Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 6,770 matching trials from the live ClinicalTrials.gov search.

Filters: Bethesda, Maryland Clear all

Conditions: Body Weight
Interventions: Not listed
Lead sponsor: National Human Genome Research Institute (NHGRI); NIH
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 1,464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer Metastatic
Interventions: [68Ga]-PSMA-R2; Drug
Lead sponsor: Advanced Accelerator Applications; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 2 more

Conditions: Liver Disease, Hepatitis D
Interventions: Peg-interferon lambda, Lonafarnib, Ritonavir; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Beta Thalassemia, Hemoglobinopathy
Interventions: Hydroxyurea; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Traumatic Amputation
Interventions: NMES (EMPI 300PV stimulator) plus standard of care, TMARP standard of care; Device · Behavioral
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 3
States / cities: San Diego, California • Bethesda, Maryland • Memphis, Tennessee

Conditions: Hypercholesterolemia, Postmenopause
Interventions: L-arginine, Estrogen; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Interventions: Idelalisib, Rituximab, Bendamustine, Ofatumumab, Fludarabine, Everolimus, Bortezomib, Chlorambucil, Lenalidomide; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 11
States / cities: Huntsville, Alabama • Los Angeles, California • Palo Alto, California + 8 more

Conditions: Colorectal Neoplasms, Colorectal Carcinoma, Colorectal Tumors
Interventions: ISIS 183750, Irinotecan; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Breast Neoplasms
Interventions: Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2, Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2, Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2; Drug
Lead sponsor: R-Pharm; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 60
States / cities: Tuscaloosa, Alabama • La Jolla, California • Southington, Connecticut + 52 more

Conditions: Hepatitis-Associated Aplastic Anemia
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 100 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Retinal Vein Occlusion
Interventions: Minocycline, Placebo, Bevacizumab; Drug · Other
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Recurrent B Acute Lymphoblastic Leukemia
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Mitoxantrone, Mitoxantrone Hydrochloride, Pegaspargase, Pharmacological Study, Radiation Therapy, Therapeutic Hydrocortisone, Thioguanine, Vincristine, Vincristine Sulfate; Procedure · Drug · Biological + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 31 Years
Enrollment: 669 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 166
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 135 more

Conditions: Carpal Tunnel
Interventions: USCTR, mOCTR; Device · Procedure
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years to 89 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Tipranavir; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 997 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 86
States / cities: Phoenix, Arizona • Berkeley, California • Fountain Valley, California + 56 more

Conditions: Healthy
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 21 Years to 65 Years
Enrollment: 222 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: COVID-19
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Acute Episode of Overt Hepatic Encephalopathy, Hepatic Encephalopathy
Interventions: ornithine phenylacetate, placebo intravenous infusion; Drug
Lead sponsor: Ocera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 49
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Coronado, California + 29 more

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Ibrutinib, Obinutuzumab, Observation Activity, Venetoclax; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 65 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 857
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 555 more

Conditions: Premenstrual Syndrome, Depression
Interventions: Not listed
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Central Nervous System Disease, Cerebrovascular Accident, Stroke
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Lymphoma, Follicular
Interventions: Bevacizumab, Rituximab; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 22
States / cities: Jonesboro, Arkansas • Fort Myers, Florida • Jacksonville, Florida + 17 more

Conditions: Brain Tumor, Astrocytoma, Astroglioma, Glioblastoma, Gliosarcoma
Interventions: Zotiraciclib (TG02), Temozolomide (TMZ); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Spinal and Bulbar Muscular Atrophy
Interventions: BVS857, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Orange, California • Bethesda, Maryland • Columbus, Ohio

Conditions: Normal Physiology
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Patient Perspectives and Doctor Visits

68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)

Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon

Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia)

Strength, Pain and Function in Operation Iraqi Freedom/Operation Enduring Freedom Amputees: A Nurse-Managed Program

Vascular and Metabolic Effects of Hormone Therapy Combined With L-Arginine in Postmenopausal Women

Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

ISIS 183750 With Irinotecan for Advanced Solid Tumors or Colorectal Cancer

Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer

Collection of Biological Samples From Patients With Hepatitis-Associated Aplastic Anemia

Minocycline to Treat Branch Retinal Vein Occlusion

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

Clinical Outcomes of USCTR vs. mOCTR

Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects

Investigating the Cognitive Processes That Underlie Social Knowledge and Behavior

An Observational Study of Neurologic Function After COVID-19 Infection

Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

Combined Hormone Replacement in Menstrually-Related Mood Disorders

Influence of Area of Brain Damage on Brain Reorganization After Chronic Stroke

A Study of Rituximab and Bevacizumab in Patients With Follicular Non-Hodgkin's Lymphoma

Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma

Safety, Tolerability, and Efficacy of BVS857 in Patients With Spinal and Bulbar Muscular Atrophy

Reproducibility of a Fecal Occult Blood Test Device for Gut Microbiota Analyses